Pulmonary Complications of Immunotherapy

Area of Science:

• Oncology
• Immunology
• Pulmonology

Background:

• Immune checkpoint inhibitor (ICI) therapy has transformed lung cancer treatment.
• While generally safer than chemotherapy, ICIs can cause immune-related adverse events (irAEs).
• irAEs are significant, poorly understood complications that can limit treatment and pose risks.

Purpose of the Study:

• To highlight the importance of understanding and managing irAEs in lung cancer patients treated with ICIs.
• To emphasize the need for further prospective research on irAEs.
• To underscore the clinical and radiographic diversity of ICI-related pneumonitis.

Main Methods:

• Review of current understanding and clinical experience with ICI therapy in lung cancer.
• Analysis of the characteristics of immune-related adverse events, focusing on pneumonitis.
• Assessment of existing guidelines and identification of research gaps.

Main Results:

• ICI therapy is a major advancement in treating advanced lung cancer.
• Immune-related adverse events, including pneumonitis, are a critical concern.
• Current management strategies rely on consensus and require further validation.

Conclusions:

• Clinical vigilance is essential for managing lung cancer patients undergoing ICI therapy.
• ICI-related pneumonitis presents as a diverse clinical and radiographic syndrome.
• Prospective investigations are necessary to improve the diagnosis and management of irAEs.